Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sic
Go back to Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sic| Advanced Battery Technologies (NASDAQ: GBT) | Delayed: 68.49 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.49 | 52 Week High | $55.74 | |||
| Open | $68.49 | 52 Week Low | $12.24 | |||
| Day High | $68.49 | P/E | 273.96 | |||
| Day Low | $68.49 | EPS | $0.25 | |||
| Volume | 2 | |||||
